Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer.
To investigate the relationships between the expression of MUC5B and clinicopathological parameters, the expression of MUC5B was immunohistochemically studied. MUC5B expression was observed in 129 of 198 (65.2%) adenocarcinomas and in 4 of 49 (8.2%) squamous cell carcinomas (P < 0.00001). MUC5B expression was significantly associated with poorer differentiation (P = 0.0303), higher pathological TNM stage (p = 0.0153) and poorer prognosis of adenocarcinoma patients (P = 0.0017). Multivariable analysis with Cox proportional hazards models confirmed that MUC5B expression increased the hazard of death after adjusting for other clinicopathological factors (HR = 2.66; 95%CI, 1.26-5.61). We also immunohistochemically evaluated TTF-1 expression and found that the combination of MUC5B with TTF-1 is a useful marker for adenocarcinomas. The diagnostic accuracies of TTF-1 and MUC5B for adenocarcinoma were 83.8% and 70.4%, respectively. The accuracy increased to 94.3% when the two factors were combined. In survival analysis, the MUC5B(High)/TTF-1(-) group was significantly associated with a poorer outcome compared with the MUC5B(Low)/TTF-1(+) group (p < 0.0001). The present study suggested that the combination of MUC5B and TTF-1 expression is useful for discriminating adenocarcinomas from squamous cell carcinomas, yielding prognostic significance in patients with lung adenocarcinoma.
1] Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan [2] Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
Ryo
R
Nagashio
Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan.
Junpei
J
Ueda
Department of Respiratory Medicine, School of Medicine, Kitasato University, Kanagawa, Japan.
Shinichiro
S
Ryuge
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kitasato University, Kanagawa, Japan.
Hiroyasu
H
Nakashima
Department of Pathology, School of Medicine, Kitasato University, Kanagawa, Japan.
Shi-Xu
SX
Jiang
Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan.
Makoto
M
Kobayashi
Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan.
Kengo
K
Yanagita
Department of Respiratory Medicine, School of Medicine, Kitasato University, Kanagawa, Japan.
Ken
K
Katono
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kitasato University, Kanagawa, Japan.
Yukitoshi
Y
Satoh
Department of Respiratory Medicine, School of Medicine, Kitasato University, Kanagawa, Japan.
Noriyuki
N
Masuda
Department of Pathology, School of Medicine, Kitasato University, Kanagawa, Japan.
Yoshiki
Y
Murakumo
Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
Kazuo
K
Hachimura
1] Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan [2] Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
Yuichi
Y
Sato
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D055257:Mucin-5B / Q000235:genetics*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D014157:Transcription Factors
D004268:DNA-Binding Proteins; C524578:MUC5B protein, human; D055257:Mucin-5B; C504003:TTF1 protein, human; D014157:Transcription Factors